Corixa Corporation
Phase I trial of CRX-675 initiated in patients with seasonal allergic rhinitis
Published in Pharma Law Weekly, June 1st, 2004
The trial is being conducted in the United States under a U.S. Food and Drug Administration (FDA) Investigational New Drug Application (IND). CRX-675 is a member of Corixa's family of proprietary compounds that interact with toll-like receptor 4 (TLR4).
As a TLR4 agonist, CRX-675 may influence innate immunity, the body's first line of defense against a variety of infectious pathogens. TLR4 agonists can also affect the immune system's response...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Law Weekly
Source: Pharma Law Weekly (2004-06-01)
More Articles from Pharma Law Weekly
- 4SC AG
Agreement signed to develop compounds for autoimmune disorders - Advanced Biotherapy, Inc.
Agreement signed for humanized antibody to interferon-gamma - Cancer Treatment
Oklahoma Cancer treatment bill signed - Chimerix, Inc.
Patent granted for CMX001, an orally-active smallpox therapeutic - Correctional Health
Florida inmates detained under Jimmy Ryce Act sue over treatment - Diomed Holdings, Inc.
Device firm reports 39% increase in revenues - More from this issue of Pharma Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
